acut
respiratori
distress
syndrom
ard
accompani
sever
lung
inflamm
induc
variou
diseas
despit
sever
symptom
therapeut
strategi
ineffect
high
mobil
group
box
identifi
origin
dna
bind
protein
propos
mediat
acut
lung
injuri
addit
anticoagul
activ
recombin
thrombomodulin
rtm
possess
abil
suppress
inflammatori
respons
neutral
regulatori
treg
cell
lung
report
modifi
innat
immun
respons
resolut
acut
lung
injuri
present
studi
investig
therapeut
effect
rtm
contribut
treg
cell
effect
mous
model
sever
ard
mice
receiv
sequenti
intratrach
administr
agalactosylceramid
agalc
lipopolysaccharid
lp
result
develop
sever
ard
level
lung
increas
higher
level
ard
mice
compar
mice
treat
lp
alon
express
infiltr
neutrophil
macrophag
lung
treg
cell
reduc
significantli
lung
ard
mice
compar
mice
treat
lp
alon
rtm
administr
prolong
surviv
time
amelior
develop
ard
associ
increas
treg
cell
synthesi
interleukin
il
transform
growth
factor
tgf
b
lung
result
suggest
involv
develop
sever
ard
rtm
show
therapeut
effect
promot
accumul
treg
cell
inflammatori
site
acut
respiratori
distress
syndrom
ard
character
diffus
lung
injuri
sever
hypoxaemia
variou
pathogen
condit
associ
high
mortal
approxim
lung
injuri
trigger
inhal
caus
agent
via
airborn
rout
design
direct
lung
injuri
develop
context
system
disord
sepsi
design
indirect
lung
injuri
direct
lung
injuri
type
ard
report
occur
infect
sever
acut
respiratori
syndrom
sar
viru
highli
pathogen
avian
influenza
viru
follow
chemic
physic
hazard
bronchial
aspir
gastric
content
drown
serum
level
interferon
ifn
g
tumour
necrosi
factor
tnf
interleukin
il
elev
fatal
human
influenza
viru
infect
sever
cytokin
chemokin
level
includ
tnfa
increas
bronchoalveolar
lavag
bal
fluid
case
acutephas
ard
anim
model
direct
lung
injuri
induc
intratrach
administr
lipopolysaccharid
lp
acut
robust
influx
inflammatori
cell
lung
observ
howev
inflammatori
chang
resolv
complet
within
h
neither
alveolar
epitheli
injuri
vascular
leakag
typic
histolog
featur
ard
observ
recent
report
anim
model
sever
ard
establish
sensit
mice
agalactosylceramid
agalc
potent
activ
natur
killer
nk
cell
follow
challeng
lipopolysaccharid
lp
model
mice
die
rapidli
diffus
alveolar
damag
lung
accompani
larg
increas
ifng
tnfa
product
high
mobil
group
box
identifi
origin
dna
bind
protein
also
potent
proinflammatori
properti
exposur
neutrophil
macrophag
induc
nuclear
transloc
nuclear
factorkappa
b
nfkb
enhanc
product
proinflammatori
cytokin
includ
tnfa
least
part
interact
tolllik
receptor
tlr
receptor
advanc
glycat
end
product
rage
propos
recent
one
late
mediat
lpsinduc
sepsi
lethal
intratrach
inject
result
develop
acut
pulmonari
inflamm
blockad
decreas
sever
lpsinduc
acut
lung
injuri
ali
haemorrhageinduc
ali
thrombomodulin
tm
thrombin
receptor
endotheli
cell
surfac
import
player
natur
anticoagul
antiinflammatori
system
tm
uniqu
antiinflammatori
properti
ntermin
lectinlik
domain
bind
therebi
suppress
inflamm
recombin
tm
rtm
human
solubl
tm
extracellular
domain
includ
activ
site
similar
tm
rtm
possess
abil
suppress
inflammatori
respons
addit
anticoagul
activ
recent
ogawa
cowork
report
solubl
rtm
improv
respiratori
dysfunct
surviv
patient
sepsi
regulatori
treg
cell
subset
cell
express
surfac
marker
transcript
factor
forkhead
box
protein
treg
cell
implic
control
autoreact
cell
vivo
treg
cell
exert
suppress
effect
increas
array
pathophysiolog
event
includ
regul
immun
respons
inflammatori
condit
recent
dalessio
cowork
report
treg
cell
modifi
innat
immun
respons
resolut
ali
caus
lp
treatment
present
studi
hypothes
involv
inflammatori
respons
develop
sever
ard
model
also
question
whether
rtm
treatment
improv
inflammatori
respons
clinic
cours
ard
mice
treg
cell
contribut
benefici
effect
treatment
address
hypothesi
question
examin
kinet
secret
bal
fluid
assess
histolog
local
cell
lung
ard
mice
also
examin
effect
rtm
treatment
surviv
inflammatori
respons
mice
found
pulmonari
level
increas
ard
mice
mice
treat
lp
alon
rtm
administr
amelior
develop
patholog
condit
increas
treg
cell
lung
ard
mice
nk
celldefici
mice
knockout
ko
mice
establish
target
delet
gene
segment
backcross
eight
gener
kindli
provid
dr
toshinori
nakayama
graduat
school
medicin
chiba
univers
chiba
japan
dr
masaru
taniguchi
riken
research
center
allergi
immunolog
yokohama
japan
mice
mice
bred
pathogenfre
environ
institut
anim
experiment
tohoku
univers
graduat
school
medicin
mice
use
experi
week
age
experiment
protocol
describ
present
studi
approv
ethic
review
committe
anim
experiment
tohoku
univers
agalc
purchas
funakoshi
tokyo
japan
dissolv
dimethyl
sulphoxid
dmso
sigmaaldrich
st
loui
mo
usa
concentr
mgml
dilut
phosphatebuff
salin
pb
final
concentr
dmso
invivo
use
lp
escherichia
coli
purchas
sigmaaldrich
induc
sever
ard
mice
anaesthet
use
intraperiton
inject
mgkg
pentobarbit
abbott
laboratori
north
chicago
il
usa
restrain
small
board
ml
agalc
mg
inject
trachea
mous
use
cathet
terumo
tokyo
japan
twentyfour
h
later
ml
lp
mg
administ
via
rout
control
mice
receiv
ml
dmsocontain
pb
dpb
instead
agalc
trachea
andor
h
later
ml
pb
instead
lp
administ
use
rout
rtm
provid
asahi
kasei
pharma
chiba
japan
mice
administ
rtm
dose
mgkg
mgkg
intraperiton
everi
h
begin
h
lp
inject
timecours
rtm
administr
illustr
fig
lung
specimen
obtain
mice
fix
buffer
formalin
dehydr
embed
paraffin
section
cut
stain
haematoxylin
eosin
h
e
use
standard
stain
procedur
biomed
research
core
anim
patholog
platform
tohoku
univers
graduat
school
medicin
measur
histolog
evid
tissu
injuri
use
lung
injuri
score
system
recommend
american
thorac
societi
at
lung
injuri
score
system
paramet
includ
neutrophil
alveolar
space
neutrophil
interstiti
space
hyalin
membran
proteinac
debri
fill
airspac
alveolar
septal
thicken
least
random
highpow
field
total
magnif
score
independ
blind
fashion
five
histolog
find
grade
use
threetier
scheme
summar
tabl
sum
five
independ
variabl
shown
tabl
weight
accord
relev
ascrib
featur
at
committe
normal
number
field
evalu
lung
tissu
agalcerlpstr
mice
fix
neutral
buffer
formalin
paraffinembed
block
cut
section
mount
onto
slide
specimen
deparaffin
rehydr
hightemperatur
antigen
retriev
involv
boil
slide
citrat
buffer
mm
per
litr
ph
min
follow
block
rabbit
serum
sampl
incub
primari
antibodi
polyclon
chicken
immunoglobulin
ig
antibodi
dilut
shinotest
sagamihara
japan
overnight
endogen
peroxidas
activ
block
treatment
block
solut
min
wash
slide
incub
biotinyl
rabbit
antichicken
igi
antibodi
acri
antibodi
gmbh
herford
germani
dilut
pb
incub
horseradish
peroxidaseconjug
streptavidin
nichirei
tokyo
japan
wash
slide
incub
diaminobenzidin
substrat
counterstain
carrazzi
haematoxylin
solut
wako
osaka
japan
chicken
igi
shinotest
dilut
pb
use
nonimmun
control
mice
kill
variou
interv
lp
exposur
chest
open
trachea
cannul
g
intraven
iv
cathet
ml
pb
infus
intratrach
withdrawn
procedur
perform
three
time
bal
fluid
centrifug
g
min
supernat
store
cytokin
measur
collect
bal
fluid
pulmonari
circul
rins
inject
ml
pb
right
ventricl
next
lung
harvest
store
either
ml
pb
analysi
cytokin
interstiti
lung
area
volum
nipro
osaka
japan
medium
supplement
fetal
calf
serum
fc
biowest
franc
analysi
lung
interstiti
leucocyt
lung
store
pb
homogen
centrifug
g
min
supernat
store
cytokin
measur
surfac
antigen
express
analysi
homogen
lung
cell
incub
min
vigor
shake
medium
supplement
mm
hepe
sigmaaldrich
fc
contain
uml
collagenas
mgml
dnase
sigmaaldrich
tissu
fragment
dead
cell
remov
pass
solut
nylon
mesh
centrifug
g
min
cell
pellet
resuspend
ml
vv
percol
pharmacia
uppsala
sweden
layer
onto
ml
vv
percol
centrifug
g
min
room
temperatur
cell
interfac
collect
wash
three
time
count
use
haemocytomet
lung
interstiti
leucocyt
preincub
antifcgriiiii
monoclon
antibodi
mab
prepar
cultur
supernat
hybridoma
cell
clone
use
protein
g
column
kit
kirkegaard
perri
laboratori
gaithersburg
md
usa
ice
min
pb
contain
fc
sodium
azid
cell
stain
use
fluorescein
isothiocyan
fitc
conjug
clone
bd
bioscienc
franklin
lake
nj
usa
pacif
blueconjug
clone
biolegend
san
diego
ca
usa
fitcconjug
control
rat
clone
biolegend
number
field
refer
american
thorac
societi
pacif
blueconjug
control
rat
clone
biolegend
cell
surfac
stain
cell
stain
intracellular
cell
fix
permeabil
stain
buffer
ebiosci
san
diego
ca
usa
stain
phycoerythrin
pe
conjug
mab
clone
ebiosci
control
rat
clone
biolegend
stain
cell
analys
use
flow
cytomet
fac
canto
ii
bd
bioscienc
data
collect
individu
cell
use
forward
fsc
sidescatt
ssc
paramet
limit
lymphocyt
popul
ifng
tnfa
concentr
lung
homogen
supernat
bal
fluid
measur
use
enzymelink
immunosorb
assay
elisa
captur
biotinyl
develop
antibodi
bd
bioscienc
detect
limit
pgml
pgml
respect
transform
growth
factor
tgfb
concentr
measur
use
elisa
kit
biolegend
ebiosci
tgfb
shinotest
detect
limit
pgml
pgml
pgml
pgml
ngml
respect
cytokin
concentr
bal
fluid
normal
protein
content
measur
detergentcompat
dc
protein
assay
biorad
hercul
ca
usa
data
analysi
conduct
use
jmp
version
softwar
sa
institut
inc
cari
nc
usa
macintosh
comput
data
express
median
interquartil
statist
analysi
group
perform
use
analysi
varianc
posthoc
analysi
fisher
protect
least
signific
differ
test
surviv
data
analys
use
logrank
test
pvalu
consid
signific
report
recent
play
critic
role
lpsinduc
ali
therefor
address
possibl
involv
pathogenesi
sever
ard
first
measur
secret
lung
shown
fig
concentr
bal
fluid
increas
threefold
h
sixfold
h
mice
treat
agalcerlp
compar
level
lp
treatment
reduc
slightli
h
mice
treat
agalcerlp
contrast
dpb
lpstreat
mice
show
gradual
increas
level
h
level
lower
h
dpbslpstreat
mice
treat
agalcerlp
agalcerpbstr
mice
level
increas
h
equival
level
agalcerlpstr
mice
thereaft
level
reduc
h
addit
bal
fluid
level
agalcerlpstr
mice
reduc
h
mice
compar
wildtyp
mice
indic
nk
cell
essenti
secret
lung
sever
ard
mice
fig
determin
cell
contribut
secret
lung
immunohistochem
analysi
perform
lung
section
agalcerlpstr
mice
receiv
lp
h
shown
fig
express
detect
cytoplasm
neutrophil
macrophag
infiltr
alveolar
space
intraalveolar
septa
contrast
stain
posit
bronchial
alveolar
epitheli
cell
nuclei
agalcerlpstr
mice
group
data
shown
result
suggest
neutrophil
macrophag
accumul
inflammatori
site
may
contribut
secret
develop
sever
ard
earlier
studi
ifng
tnfa
shown
critic
cytokin
develop
sever
ard
therefor
studi
measur
concentr
cytokin
bal
fluid
lung
homogen
shown
fig
ifng
product
bal
fluid
began
increas
h
lp
administr
agalcerlpstr
mice
product
lung
homogen
increas
peak
level
h
decreas
h
increas
h
contrast
ifng
product
dpbslpstreat
mice
prelp
treatment
level
lower
level
agalcerlpstr
mice
timepoint
tnfa
product
bal
fluid
began
increas
h
lp
treatment
reach
peak
level
h
decreas
h
agalcerlpstr
mice
product
lung
homogen
increas
peak
level
h
decreas
h
h
addit
dpbslpstreat
mice
show
similar
tnfa
product
kinet
bal
fluid
lung
homogen
although
level
much
lower
agalcerlpstr
mice
antiinflammatori
effect
rtm
anticoagul
drug
occur
potenti
neutral
inhibit
order
determin
effect
rtm
develop
sever
ard
agalcerlpstr
mice
receiv
rtm
intraperiton
mortal
observ
rtm
administr
dose
mg
kg
mgkg
increas
surviv
agalc
lpstreat
mice
significantli
compar
receiv
pb
treatment
fig
also
perform
histolog
analysi
examin
effect
treatment
inflammatori
chang
lung
sever
ard
mice
less
infiltr
inflammatori
cell
alveolar
space
intraalveolar
septa
fewer
oedemat
chang
interstiti
area
rtmtreat
mice
compar
control
mice
h
lp
administr
fig
object
evalu
inflammatori
chang
quantifi
histolog
chang
tissu
injuri
use
lung
injuri
score
system
shown
fig
lung
injuri
score
significantli
lower
rtmtreat
mice
control
mice
result
indic
rtm
effect
inhibit
develop
sever
ard
caus
agalc
sensit
lp
challeng
earlier
studi
ifng
tnfa
shown
critic
cytokin
develop
sever
ard
caus
agalcerlpstreat
therefor
present
research
determin
effect
rtm
product
ifng
tnfa
lung
measur
concentr
cytokin
bal
fluid
lung
homogen
h
agalcerlpstr
mice
receiv
either
rtm
pb
rtm
treatment
show
signific
effect
product
ifng
tnfa
bal
fluid
lung
homogen
h
lp
treatment
tabl
result
suggest
rtm
attenu
develop
sever
ard
differ
manner
suppress
ifng
tnfa
previou
studi
treg
cell
shown
involv
resolut
ali
caus
intratrach
lp
administr
occur
sever
ard
model
treg
cell
identifi
cell
hypothes
reduc
agalcerlpstr
mice
compar
dpbslpstreat
mice
shown
fig
proport
treg
cell
significantli
lower
lung
lymphocyt
agalcerlpstr
mice
dpbslpstreat
mice
addit
administr
rtm
result
signific
increas
treg
cell
lung
lymphocyt
agalcerlpstr
mice
compar
mice
receiv
pb
result
suggest
recoveri
reduc
treg
cell
lung
sever
ard
mice
may
relat
benefici
effect
rtm
treatment
also
compar
effect
rtm
tgfb
synthesi
lung
sever
ard
mice
cytokin
known
play
key
role
antiinflammatori
effect
treg
cell
shown
fig
rtm
administr
increas
level
cytokin
significantli
lung
homogen
agalcerlpstr
mice
compar
mice
receiv
pb
result
suggest
benefici
effect
rtm
treatment
sever
ard
mice
may
occur
increas
product
antiinflammatori
cytokin
tgfb
present
studi
determin
involv
pathogenesi
sever
ard
use
mous
model
establish
sensit
agalc
challeng
lp
main
find
follow
level
bal
fluid
began
increas
h
peak
h
exposur
lp
ard
mice
level
higher
ard
mice
mice
ali
caus
lp
treatment
alon
ii
neutrophil
lung
injuri
score
section
evalu
accord
score
system
describ
tabl
data
shown
median
interquartil
dot
repres
individu
mous
p
ns
signific
compar
mice
treat
pb
macrophag
infiltr
lung
stain
antibodi
ard
mice
iii
ifng
tnfa
product
detect
higher
level
ard
mice
ali
mice
iv
rtm
prolong
surviv
amelior
inflammatori
chang
lung
ard
mice
v
rtm
increas
proport
treg
cell
product
tgfb
lung
ard
mice
result
suggest
may
involv
pathogenesi
sever
ard
amelior
ard
rtm
probabl
occur
revers
reduct
treg
cell
antiinflammatori
cytokin
product
previou
research
reveal
one
key
mediat
pathophysiolog
lung
injuri
ueno
cowork
report
level
bal
fluid
higher
mice
treat
lp
tabl
effect
recombin
thrombomodulin
interferon
ifn
g
tumour
necrosi
factor
tnf
product
lung
sever
acut
respiratori
distress
syndrom
ard
mice
mice
receiv
agalactosylceramid
agalc
lipopolysaccharid
lp
treatment
inject
intraperiton
recombin
thrombomodulin
rtm
phosphatebuff
salin
pb
everi
h
begin
h
lp
challeng
ifng
tnfa
concentr
bronchoalveolar
lavag
bal
fluid
pgmg
protein
lung
homogen
pgml
measur
h
lp
treatment
measur
bal
fluid
normal
respect
protein
content
valu
repres
median
interquartil
rang
four
five
mice
control
mice
present
studi
level
bal
fluid
higher
ard
mice
mice
ali
caus
lp
alon
suggest
robust
secret
may
contribut
sever
lung
injuri
fatal
outcom
known
activ
nk
cell
rapidli
produc
larg
amount
ifng
recent
shown
ifng
secret
nk
cell
play
critic
role
develop
sever
lung
injuri
model
addit
ifng
report
induc
releas
invitro
experi
thu
ifng
secret
nk
cell
may
upstream
mediat
releas
agreement
possibl
result
show
larg
amount
ifng
secret
lung
level
increas
agalcerlpstr
mice
compar
mice
group
releas
reduc
basal
level
nk
celldefici
mice
tnfa
report
contribut
partial
ifnginduc
releas
invitro
experi
tnfa
alon
also
induc
releas
current
studi
robust
amount
tnfa
secret
lung
agalcerlpstr
mice
reach
peak
level
higher
level
mice
ali
caus
lp
treatment
alon
howev
administr
antitnfa
mab
decreas
concentr
bal
fluid
lung
homogen
data
shown
thu
tnfa
may
involv
greatli
releas
lung
ard
mice
addit
measur
concentr
bal
fluid
model
cytokin
report
increas
case
acutephas
ard
howev
contrast
ifng
tnfa
signific
increas
detect
level
agalcerlpstr
mice
compar
dpb
lpstreat
mice
except
h
fig
investig
necessari
defin
precis
role
inflammatori
cytokin
develop
ard
stabl
condit
exist
mainli
nucleu
dna
bind
protein
nuclear
transloc
cytoplasm
releas
extracellular
milieu
cell
receiv
threat
stimulu
ueno
cowork
demonstr
present
nucleu
cytoplasm
alveolar
macrophag
mice
ali
caus
lp
present
studi
immunohistochem
analysi
reveal
detect
cytoplasm
neutrophil
macrophag
infiltr
alveolar
space
intraalveolar
septa
indic
neutrophil
macrophag
cellular
sourc
mice
sever
ard
caus
agalcerlp
treatment
thu
leucocyt
accumul
inflammatori
site
may
play
import
role
secret
develop
ard
rtm
known
bind
ntermin
lectinlik
domain
suppress
inflammatori
respons
previou
studi
abeyama
et
al
rtm
shown
decreas
local
leucocyt
accumul
tnfa
product
ultraviolet
uv
irradi
skin
similarli
nagato
cowork
report
rtm
reduc
serum
tnfa
level
mous
model
lpsinduc
system
inflammatori
respons
syndrom
mediat
antagonist
effect
similar
earlier
investig
result
current
studi
demonstr
rtm
treatment
improv
clinic
cours
amelior
lung
inflammatori
respons
sever
ard
mice
howev
treatment
affect
product
ifng
tnfa
play
critic
role
develop
sever
lung
injuri
model
find
unexpect
similarli
product
affect
rtm
treatment
tabl
thu
research
requir
clarifi
inflammatori
cytokin
affect
rtm
order
defin
mechan
benefici
effect
rtm
sever
ard
mice
address
possibl
involv
treg
cell
known
regul
immun
respons
inflammatori
condit
secret
antiinflammatori
cytokin
tgfb
present
studi
proport
treg
cell
lung
significantli
lower
sever
ard
mice
compar
mice
treat
lp
alon
earli
h
exposur
lp
rtm
increas
treg
cell
lung
sever
ard
mice
thu
result
strongli
support
possibl
involv
treg
cell
determin
outcom
lung
injuri
reduc
treg
cell
lead
develop
sever
ard
wherea
sever
lung
injuri
amelior
increas
proport
treg
cell
increas
level
treg
cell
detect
innat
phase
immun
respons
suggest
involv
natur
treg
cell
rather
induc
treg
cell
develop
naiv
cell
upon
antigen
stimul
pathogen
mechan
sever
ard
research
examin
sever
lung
injuri
interfer
treg
cell
accumul
activ
nk
cell
robust
secret
relat
phenomenon
tgfb
possess
potent
regulatori
activ
immun
inflammatori
respons
cytokin
report
play
critic
role
suppress
inflamm
immun
respons
mediat
treg
cell
result
present
studi
demonstr
product
tgfb
augment
lung
rtmtreat
mice
compar
control
mice
agre
previou
research
result
suggest
rtm
may
exert
benefici
effect
develop
sever
lung
injuri
promot
product
antiinflammatori
cytokin
treg
cell
conclus
present
studi
demonstr
bal
fluid
level
secret
inflammatori
leucocyt
associ
sever
lung
injuri
administr
rtm
show
clinic
effect
protect
ard
mice
sever
lung
injuri
fatal
outcom
associ
revers
reduc
treg
cell
accumul
amelior
product
tgfb
lung
find
provid
import
inform
develop
novel
therapeut
strategi
manipul
treg
cell
human
ard
high
mortal
rate
hospit
intens
care
unit
limit
avail
therapeut
agent
howev
precis
mechan
treg
cell
involv
progress
sever
lung
injuri
ard
yet
determin
moreov
clinic
set
patient
sever
ard
must
receiv
proper
treatment
includ
drug
mechan
ventil
affect
patholog
condit
without
treatment
anim
model
may
reflect
patholog
mechan
accur
research
focu
issu
necessari
translat
practic
medicin
addit
support
inform
may
found
onlin
version
articl
publish
websit
fig
interleukin
il
product
lung
sever
acut
respiratori
distress
syndrom
ard
mice
mice
receiv
intratrach
administr
lipopolysaccharid
lp
phosphatebuff
salin
pb
h
administr
agalactosylceramid
agalc
dimethylsulphoxid
dmso
contain
phosphatebuff
salin
dpb
via
rout
concentr
bronchoalveolar
lavag
bal
fluid
measur
h
treatment
lp
pb
measur
bal
fluid
normal
respect
protein
content
data
shown
median
interquartil
dot
repres
individu
mous
p
tabl
effect
recombin
thrombomodulin
interleukin
il
product
lung
sever
acut
respiratori
distress
syndrom
ard
mice
